IDEXX LABORATORIES INC
IDXXNASDAQTrading Snapshot
- Day Range
- $526.58 β $537.36
- 52-Week Range
- $500.61 β $769.98
- Volume
- $3.69B
- Avg Volume
- $3.56B
- Shares Outstanding
- 78.9M
- Next Earnings
- Nov 10, 2026
Fundamentals Snapshot
- Annual Revenue
- $4.30B
- Last Q Revenue
- $1.22B
- P/E Ratio
- 37.2
- P/S Ratio
- 9.2x
- EPS (TTM)
- $14.23
- Dividend Yield
- 0.00%
- Dilution (1yr)
- β2.3%
Why Investors Own IDXX
- βHigh-growth profile β revenue up +46.2% YoY with expanding US Equity exposure.
- βHealthy economics β 75% gross margin and 15% free-cash-flow margin.
- βNew products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
IDEXX LABORATORIES INC
IDXXAbout IDEXX LABORATORIES INC
IDEXX Laboratories, Inc. is a global enterprise focused on creating, producing, and distributing a wide array of products and services. Its primary client base includes companion animal veterinary practices, the livestock and poultry industries, dairy operations, and water quality testing sectors. The company organizes its operations across several key divisions: the Companion Animal Group (CAG), Water Quality Products, Livestock, Poultry, and Dairy (LPD), and additional segments. For companion animals, IDEXX offers a comprehensive suite of point-of-care veterinary diagnostic tools, such as instruments, consumables, and rapid assay kits. It also provides reference laboratory diagnostic and consultation services, alongside practice management and diagnostic imaging solutions for veterinarians. Furthermore, the company supports the biomedical research community with health monitoring, biological materials testing, and laboratory animal diagnostic instruments and services. In the livestock, poultry, and dairy markets, IDEXX supplies diagnostic and health-monitoring solutions. Its water testing portfolio includes products designed to detect various microbiological contaminants, notably the Colilert, Colilert-18, and Colisure tests for total coliforms and E. coli, as well as Enterolert, Pseudalert, Filta-Max, Filta-Max xpress, Legiolert, and Quanti-Tray products. Beyond these, IDEXX extends its reach to human point-of-care medical diagnostics, offering electrolyte and blood gas analyzers, and SARS-CoV-2 RT-PCR tests. Other key offerings encompass in-clinic chemistry, blood and urine chemistry, hematology, and SediVue Dx analyzers, as well as SNAP rapid assay test kits. Veterinary software and services for both independent clinics and large corporate veterinary groups are also part of its offerings. The company distributes its extensive product and service catalog through its own dedicated marketing, customer service, sales, and technical service teams, supplemented by independent distributors and other resellers. IDEXX Laboratories, Inc. was established in 1983 and maintains its headquarters in Westbrook, Maine.
Otter Score Breakdown
How it's scoredFive components, each rated 1β5β and equally weighted (20%), averaged to a 0β100 score:π Quality β gross marginπ Growth β revenue YoYβοΈ Valuation β P/S ratioβ‘ Momentum β 30-day price changeπ§ Dilution β 1-yr share issuance (buybacks score higher)Analyst Price Target
βLatest News & Updates

Should You Continue to Hold IDXX Stock in Your Portfolio?
IDEXX's CAG growth, expanding software adoption and global gains face headwinds from FX and weaker U.S. vet visits.

IDEXX Laboratories Highlights Diagnostic Pipeline, Reaffirms Long-Term Growth Targets
IDEXX Laboratories (NASDAQ: IDXX) executives highlighted the company's diagnostic innovation pipeline, recurring-revenue growth and commercial investments during the Morgan Stanley Global Healthcare Conference, while rea

IDEXX Highlights Diagnostics Growth Drivers, Cancer Testing at Morgan Stanley Conference
IDEXX Laboratories (NASDAQ: IDXX) executives reiterated the company's long-term growth framework at the Morgan Stanley Global Healthcare Conference, citing demand for veterinary diagnostics, product innovation, commercia

IDEXX Stock Gains Following the Acquisition of CoVet
IDXX shares rise 0.6% after the company acquires CoVet, expanding its AI-native software capabilities to improve veterinary workflows, diagnostics and practice performance.

IDEXX Expands Faecal Dx Antigen Testing Platform in the United Kingdom with Taeniid Tapeworm Detection
WESTBROOK, Maine--(BUSINESS WIRE)--IDEXX expands Faecal Dxβ’ antigen testing platform in the United Kingdom with taeniid tapeworm detection for broader intestinal parasite screening.

IDEXX Laboratories Acquires CoVetAI to Advance Veterinary Workflow Intelligence
WESTBROOK, Maine--(BUSINESS WIRE)--IDEXX announces acquisition of CoVetAI to advance veterinary workflow intelligence.